Results 21 to 30 of about 28,261 (176)

EBOV sGP increases the infectivity of EBOV-sGP-KO.

, 2021
(A) Expression of EBOV GP (upper band) and sGP (lower band) EBOV-GFP and EBOV-sGP-KO was confirmed by WB analysis of using an anti-GP monoclonal antibody, ZGP42/3.7 (left; 1 μg/ml) or an anti-sGP polyclonal antibody (right; 1 μg/ml). (B, C, D) HEK293 and
Andrea Marzi (146489), Wakako Furuyama (152689), Kyle Shifflett (5599832), Heinz Feldmann (18301)   +3 more
core   +1 more source

EBOV-AbDab

, 2023
<p>Database of EBOV specific mAb sequences.</p ...
Richardson, Eve
core   +1 more source

An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice

Human Vaccines & Immunotherapeutics, 2017
Immunoinformatics tools were used to predict human leukocyte antigen (HLA) class II-restricted T cell epitopes within the envelope glycoproteins and nucleocapsid proteins of Ebola virus (EBOV) and Sudan virus (SUDV) and the structural proteins of ...
Callie E. Bounds, Frances E. Terry, Leonard Moise, Drew Hannaman, William D. Martin, Anne S. De Groot, John J. Suschak, Lesley C. Dupuy, Connie S. Schmaljohn   +8 more
doaj   +1 more source

T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protectionProtection from EBOV in the absence of antibodies

Emerging Microbes and Infections, 2017
Humoral responses are essential for the protective efficacy of most Ebola virus (EBOV) candidate vaccines; however, the in vivo development of protective anti-EBOV B-cell responses is poorly defined.
Christopher L Cooper, Karen A Martins, Sabrina M Stronsky, David P Langan, Jesse Steffens, Sean Van Tongeren, Sina Bavari   +6 more
doaj   +1 more source

Staufen1 Interacts with Multiple Components of the Ebola Virus Ribonucleoprotein and Enhances Viral RNA Synthesis

mBio, 2018
Ebola virus (EBOV) genome and mRNAs contain long, structured regions that could hijack host RNA-binding proteins to facilitate infection. We performed RNA affinity chromatography coupled with mass spectrometry to identify host proteins that bind to EBOV ...
Jingru Fang, Colette Pietzsch, Palaniappan Ramanathan, Rodrigo I. Santos, Philipp A. Ilinykh, Mariano A. Garcia-Blanco, Alexander Bukreyev, Shelton S. Bradrick   +7 more
doaj   +1 more source

Serine-Arginine Protein Kinase 1 Regulates Ebola Virus Transcription

mBio, 2020
Ebola virus (EBOV) causes a severe and often fatal disease for which no approved vaccines or antivirals are currently available. EBOV VP30 has been described as a viral phosphoprotein, and nonphosphorylated VP30 is essential and sufficient to support ...
Yuki Takamatsu, Verena Krähling, Larissa Kolesnikova, Sandro Halwe, Clemens Lier, Stefan Baumeister, Takeshi Noda, Nadine Biedenkopf, Stephan Becker   +8 more
doaj   +1 more source

Copula results during the Pre-EBOV period.

, 2021
Copula results during the Pre-EBOV period.
Mahdi Ghaemi Asl (10905817), Hamid Reza Tavakkoli (11642645), Muhammad Mahdi Rashidi (11642648)   +2 more
core   +1 more source

EBOV sGP increases EBOV replication in target tissues of BALB/c mice.

, 2021
Female BALB/c mice (n = 6) were infected with 1,000 FFU of either EBOV or EBOV-sGP-KO. After 6 days, mice received an intraperitoneal injection containing DMEM (None), DMEM containing 200 μg of EBOV sGP, RESTV sGP, the equivalent amount of CP, or 100 ng ...
Andrea Marzi (146489), Wakako Furuyama (152689), Kyle Shifflett (5599832), Heinz Feldmann (18301)   +3 more
core   +1 more source

Copula results during the EBOV period.

, 2021
Copula results during the EBOV period.
Mahdi Ghaemi Asl (10905817), Hamid Reza Tavakkoli (11642645), Muhammad Mahdi Rashidi (11642648)   +2 more
core   +1 more source

An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells.

PLoS ONE, 2021
Ebola virus (EBOV), a member of the mononegaviral family Filoviridae, causes severe disease associated with high lethality in humans. Despite enormous progress in development of EBOV medical countermeasures, no anti-EBOV treatment has been approved.
Yingyun Cai, Shuiqing Yu, Xiaoli Chi, Sheli R Radoshitzky, Jens H Kuhn, Edward A Berger   +5 more
doaj   +1 more source